Tags

Type your tag names separated by a space and hit enter

[Malaria chemoprophylaxis].
Ugeskr Laeger. 2005 Oct 17; 167(42):3984-7.UL

Abstract

Malaria is a serious infection, and prevention traditionally relies on chemoprophylaxis during and after exposure. The risk of side effects from chemoprophylaxis needs to be balanced against the risk of infection, and there has been conducted only one prospective, double-blind study comparing the suspected side effects of mefloquine (Lariam), atovaquone/proguanil (Malarone), doxycycline and chloroquine/proguanil. Therefore the current recommendations are based on descriptive studies and case reports. There is a lack of data on the risk of infection in travellers, and the national statistics on the number of imported cases are not very useful as long as the total number of travellers at risk is not known. The risk to travellers is therefore estimated from data on malaria in the indigenous population, while the risk for travellers is expected to be lower. Atovaquone/proguanil has been registered in Europe for travels of up to four weeks, but in the United States there is no upper limit for the duration of use. It is not possible to prescribe efficient prophylaxis to pregnant women in the first trimester or infants below 11 kilograms of body weight travelling to tropical Africa.

Authors+Show Affiliations

Arhus Universitetshospital, Skejby Sygehus, Infektionsmedicinsk Afdeling, Arhus N. epf@sks.aaa.dk

Pub Type(s)

Comparative Study
Journal Article
Review

Language

dan

PubMed ID

16232397

Citation

Petersen, Jørgen Eskild. "[Malaria Chemoprophylaxis]." Ugeskrift for Laeger, vol. 167, no. 42, 2005, pp. 3984-7.
Petersen JE. [Malaria chemoprophylaxis]. Ugeskr Laeger. 2005;167(42):3984-7.
Petersen, J. E. (2005). [Malaria chemoprophylaxis]. Ugeskrift for Laeger, 167(42), 3984-7.
Petersen JE. [Malaria Chemoprophylaxis]. Ugeskr Laeger. 2005 Oct 17;167(42):3984-7. PubMed PMID: 16232397.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Malaria chemoprophylaxis]. A1 - Petersen,Jørgen Eskild, PY - 2005/10/20/pubmed PY - 2005/10/26/medline PY - 2005/10/20/entrez SP - 3984 EP - 7 JF - Ugeskrift for laeger JO - Ugeskr Laeger VL - 167 IS - 42 N2 - Malaria is a serious infection, and prevention traditionally relies on chemoprophylaxis during and after exposure. The risk of side effects from chemoprophylaxis needs to be balanced against the risk of infection, and there has been conducted only one prospective, double-blind study comparing the suspected side effects of mefloquine (Lariam), atovaquone/proguanil (Malarone), doxycycline and chloroquine/proguanil. Therefore the current recommendations are based on descriptive studies and case reports. There is a lack of data on the risk of infection in travellers, and the national statistics on the number of imported cases are not very useful as long as the total number of travellers at risk is not known. The risk to travellers is therefore estimated from data on malaria in the indigenous population, while the risk for travellers is expected to be lower. Atovaquone/proguanil has been registered in Europe for travels of up to four weeks, but in the United States there is no upper limit for the duration of use. It is not possible to prescribe efficient prophylaxis to pregnant women in the first trimester or infants below 11 kilograms of body weight travelling to tropical Africa. SN - 1603-6824 UR - https://www.unboundmedicine.com/medline/citation/16232397/[Malaria_chemoprophylaxis]_ L2 - https://www.diseaseinfosearch.org/result/4415 DB - PRIME DP - Unbound Medicine ER -